Clemondo Group (CLEM) investor relations material

Executive summary

• Sales increased for the eighth consecutive quarter, with a 9% year-over-year rise in Q2 2026 to 79.6 MSEK, and improved gross margin to 39.5% from 38.0%.

• Strategic investments in quality, product management, and sales enhanced growth prospects but raised the cost base.

• Cost review initiated to strengthen margins amid geopolitical turbulence and rising input costs.

• All market areas except Industry showed growth; Medical Care and Vehicle segments performed strongly.

Financial highlights

• Net sales: 79.6 MSEK (up from 73.0 MSEK year-over-year).

• EBITDA: 5.3 MSEK (4.3 MSEK), EBITDA margin 6.6% (5.9%).

• EBIT: 1.5 MSEK (0.7 MSEK), EBIT margin 1.8% (0.9%).

• Net income after tax: 0.3 MSEK (0.0 MSEK).

• Earnings per share: 0.02 SEK (0.00 SEK).

• Cash flow from operations after working capital: -0.6 MSEK (1.5 MSEK).

• Equity ratio: 53.9% (53.6%).

• Net debt: 53.2 MSEK (53.9 MSEK previous quarter).

Outlook and guidance

• Continued focus on cost control to improve margins.

• Ongoing efforts to optimize capacity and expand in Medical Care and Vehicle segments.

• Market uncertainty due to geopolitical risks and inflationary pressures.